PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial
Results of HPTN 082 - a randomized controlled trial offering PrEP to sexually active young women ages 16-25, following for 12 months. The participants were randomized to standard adherence support (counseling, 2-way SMS, adherence clubs) or enhanced adherence support (SOC + adherence feedback from intracellular TFV-DP levels in DBS). The study found high PrEP initiation, and over half of participants persisted through month 6. There was no statistical significance in adherence at 6 months between study arms. Participants were ineligible or discontinued treatment if they became pregnant.
Resource Details
- Study Type
- Randomized clinical trial (RCT)
- Year
- 2022
- Population
- Adolescent girls and young women
- Author
- Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, Pathak S, Mgodi N, Bekker LG, Donnell DJ, Wilson E, Yuha K, Anderson PL, Agyei Y, Noble H, Rose SM, Baeten JM, Fogel JM, Adeyeye A, Wiesner L, Rooney J, Delany-Moretlwe S.
More Publications & Resources
Providing PrEP to Pregnant and Breastfeeding Women
Clinical Practice Guidelines for Providing PrEP for Pregnant and Breastfeeding Populations
Guidelines on Lenacapavir for HIV Prevention and Testing Strategies for Long-Acting Injectable Pre-Exposure Prophylaxis
PrEP and PEP Guidelines-Zambia
PrEP Lenacapavir Implementation Guidelines
Provider Training Toolkit on Use of Oral and Long-acting HIV PrEP: Lenacapavir-Focused Learning Pathway (Lessons 1-4)
Provider Training Toolkit on Use of Oral and Long Acting HIV PrEP
Inclusion of Pregnant and Lactating People in the PURPOSE 1 Study: Efficacy, Safety, and Pharmacokinetics
Lenacapavir Provider Tools and Job Aids
PrEP Drug Interactions
Zambia PrEP Training Materials for Clinicians and Community Mobilisers
No results found.